GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » EV-to-EBITDA

Radiopharm Theranostics (Radiopharm Theranostics) EV-to-EBITDA : -0.30 (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Radiopharm Theranostics's enterprise value is $8.87 Mil. Radiopharm Theranostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-29.45 Mil. Therefore, Radiopharm Theranostics's EV-to-EBITDA for today is -0.30.

The historical rank and industry rank for Radiopharm Theranostics's EV-to-EBITDA or its related term are showing as below:

RDPTF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.84   Med: 0   Max: 1.2
Current: -0.33

During the past 2 years, the highest EV-to-EBITDA of Radiopharm Theranostics was 1.20. The lowest was -0.84. And the median was 0.00.

RDPTF's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs RDPTF: -0.33

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Radiopharm Theranostics's stock price is $0.0008. Radiopharm Theranostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.091. Therefore, Radiopharm Theranostics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Radiopharm Theranostics EV-to-EBITDA Historical Data

The historical data trend for Radiopharm Theranostics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics EV-to-EBITDA Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
EV-to-EBITDA
- -1.21

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA - - - - -

Competitive Comparison of Radiopharm Theranostics's EV-to-EBITDA

For the Biotechnology subindustry, Radiopharm Theranostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's EV-to-EBITDA falls into.



Radiopharm Theranostics EV-to-EBITDA Calculation

Radiopharm Theranostics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.865/-29.45
=-0.30

Radiopharm Theranostics's current Enterprise Value is $8.87 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-29.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (OTCPK:RDPTF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Radiopharm Theranostics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0008/-0.091
=At Loss

Radiopharm Theranostics's share price for today is $0.0008.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.091.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Radiopharm Theranostics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022